AEON Biopharma, Inc.

AEON Biopharma, Inc. (Nasdaq: AEON) is a clinical-stage biopharmaceutical company that completed its business combination with Priveterra Acquisition Corp, a blank-check vehicle sponsored by Priveterra LLC, in 2023. Priveterra Acquisition Corp conducted its initial public offering in 2021, targeting the healthcare and life sciences sector. AEON is focused on the development of botulinum toxin-based therapeutic candidates, with its lead program ABP-450 targeting conditions including cervical dystonia and gastroparesis. The company filed an 8-K with the SEC on June 30, 2023, reflecting a corporate event disclosure during its early tenure as a publicly listed entity following the de-SPAC transaction. Sign up at SpacDesk for full filings, timeline data, and sponsor analytics on AEON and every active SPAC in the market.